Please login to the form below

Not currently logged in
Email:
Password:

Cipla invests £100m in UK

Indian pharma company to fund both commercial and R&D activities
UK flag

India-based pharma company Cipla has made inroads into the UK with a £100m investment in both research and commercial areas.

Cipla, which is best known for its pioneering role in providing HIV treatment to developing nations, intends to launch a range of drugs in respiratory, oncology and antiretroviral indications.

The company will also put money towards R&D, clinical trials and further expansion in the UK in what is a sign of confidence in the country's ability to attract pharma investment following downsizing by the likes of Pfizer and Novartis.

UK Chancellor of the Exchequer George Osborne said: “Cipla is one of India's leading pharmaceutical firms and this decision shows the UK's international strength and attractiveness in this sector as well as its growing importance in Cipla's long term strategy.”

Cipla's chief financial officer Rajesh Garg explained that the company was attracted by the strength of the UK's NHS and by recent government efforts to improve the research environment, including the Life Sciences Strategy.

“We are very pleased to be making this investment in the UK,” said Garg. “We were impressed with the pro-active support and engagement that the UK Government and its various ministries showed in attracting Cipla to choose the UK as a key hub in our global footprint.”

11th July 2014

From: Research, Sales, Healthcare

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics